연구성과로 돌아가기
2023 연구성과별 연구자 정보 (394 / 2675)
※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Document Title | Author Full Name | Author Short Name | Index | Corresponding | Address | ResearcherID | ResearcherID Author Name | ORCID | ORCID Author Name | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
| Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma | Uronis, Hope E. | Uronis, HE | 3 | Duke Univ, Med Ctr, Durham, NC USA | ykkang@amc.seoul.kr; | |||||
| Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma | Lee, Keun-Wook | Lee, KW | 4 | Seoul Natl Univ, Bundang Hosp, Coll Med, Seongnam, South Korea | JQV-8143-2023 | Lee, Juhyung | ykkang@amc.seoul.kr; | |||
| Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma | Ng, Matthew C. H. | Ng, MCH | 5 | DukeNUS Duke Univ, Natl Canc Ctr Singapore, Natl Univ Singapore, Sch Med, Singapore, Singapore | ykkang@amc.seoul.kr; | |||||
| Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma | Enzinger, Peter C. | Enzinger, PC | 6 | Dana Farber Brigham Canc Ctr, Boston, MA USA | ykkang@amc.seoul.kr; | |||||
| Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma | Park, Se Hoon | Park, SH | 7 | Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea | ykkang@amc.seoul.kr; | |||||
| Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma | Gold, Philip J. | Gold, PJ | 8 | Swedish Canc Inst, Seattle, WA USA | ykkang@amc.seoul.kr; | |||||
| Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma | Lacy, Jill | Lacy, J | 9 | Yale Sch Med, New Haven, CT USA | ykkang@amc.seoul.kr; | |||||
| Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma | Hochster, Howard S. | Hochster, HS | 10 | Yale Sch Med, New Haven, CT USA | ykkang@amc.seoul.kr; | |||||
| Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma | Hochster, Howard S. | Hochster, HS | 10 | Rutgers Canc Inst New Jersey, New Brunswick, NJ USA | ykkang@amc.seoul.kr; | |||||
| Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma | Cheul, Sang | Cheul, S | 11 | Korea Univ, Guro Hosp, Seoul, South Korea | ykkang@amc.seoul.kr; | |||||
| Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma | Kim, Yeul Hong | Kim, YH | 12 | Korea Univ, Anam Hosp, Seoul, South Korea | ykkang@amc.seoul.kr; | |||||
| Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma | Marrone, Kristen A. | Marrone, KA | 13 | Johns Hopkins Univ, Baltimore, MD USA | ykkang@amc.seoul.kr; | |||||
| Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma | Kelly, Ronan J. | Kelly, RJ | 14 | Baylor Univ, Med Ctr, Dallas, TX USA | ykkang@amc.seoul.kr; | |||||
| Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma | Juergens, Rosalyn A. | Juergens, RA | 15 | McMaster Univ, Juravinski Canc Ctr, Hamilton, ON, Canada | 0000-0001-8627-4704 | Juergens, Rosalyn | ykkang@amc.seoul.kr; | |||
| Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma | Kim, Jong Gwang | Kim, JG | 16 | Kyungpook Natl Univ, Chilgok Hosp, Daegu, South Korea | ykkang@amc.seoul.kr; |
페이지 이동: